



**Proteomics International**

LABORATORIES LTD

**Media Release**

**14 March 2018**

**ASX code: PIQ**

## **Millions at risk of fatal Diabetic Kidney Disease says Predictive Test Leader PromarkerD at Global Launch**

PromarkerD is an advanced and accurate proteomics algorithm test system to predict the onset of kidney disease. Ninety percent of kidney function can be lost without experiencing any clinical symptoms.

- **PromarkerD, the world leading predictive diagnostic test for diabetic kidney disease, launched in Dominican Republic this month, with new markets planned in mainland USA, Mexico, Japan, Australia, China and Europe**
- **In clinical studies the PromarkerD test predicted 86% of previously disease-free patients who went on to develop chronic kidney disease within four years**
- **Average life expectancy on dialysis is 5-10 years, with dialysis estimated to cost US\$72,000 per person per year**
- **In March 2017, Frost & Sullivan identified PromarkerD as the world's leading test for diabetic kidney disease**
- **422 million people have diabetes and approximately one third are expected to develop diabetic kidney disease**
- **PromarkerD has the potential to save healthcare systems around the world billions of dollars in costs associated with treating diabetic kidney disease**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces the official product launch of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD".

The pioneering diagnostic test was launched by Proteomics International's partner Omics Global Solutions (Puerto Rico, USA) through its distributor in the Dominican Republic, Macrotech Farmacéutica, the exclusive provider of dialysis services in the country.

The successful launch represents the achievement of a key milestone in the stepped approach to commercialise the test in global markets using a range of technology platforms. Proteomics International is engaged with potential partners to bring PromarkerD to market in mainland USA, Mexico, Japan, Australia, China and Europe.

Proteomics International's Managing Director, Dr Richard Lipscombe said, "The world is now recognising the growing burden of diabetes and the importance of kidney health. We see PromarkerD as transforming the diagnosis and treatment of diabetic kidney disease and saving healthcare systems billions of dollars."

The test is being provided using the published mass spectrometry technology platform, known as a Laboratory Developed Test (LDT), and the Company expects to conclude its next licensing deal for this version of PromarkerD with a certified laboratory within weeks. Following uptake by specialised facilities, Proteomics International is focused on finalising the development of the in vitro diagnostic (IVD) immunoassay version of PromarkerD, that can be used in clinical laboratories around the world.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

PromarkerD is a predictive diagnostic blood test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017].

PromarkerD has been granted patent protection in several major jurisdictions including the USA, China and Japan [ASX: 16 August 2017, 29 January 2018], with others pending.

Further information is available through the PromarkerD web portal.

### **About Diabetes and Kidney Disease**

The International Diabetes Federation estimates 422 million adults worldwide now have diabetes, which is the major cause of kidney disease accounting for approximately 44% of new cases. One in three adult diabetics will develop chronic kidney disease (CKD).

CKD is a disorder in which patients show progressive loss of kidney (renal) function usually accompanied by excess protein in the urine (proteinuria). Ninety percent of kidney function can be lost without experiencing any symptoms and in Australia 53 people die every day from the disease. Many CKD patients progress to a need for dialysis or kidney transplant, or experience excessive mortality from cardiovascular-related diseases. The prevalence of CKD is rising and as such there is urgent need for early diagnosis and treatments that can benefit CKD patients.

Medicare spending in the USA for patients with chronic kidney disease aged 65 and older exceeded US\$50 billion in 2013, and represented 20% of all Medicare spending in this age group.

### **About Omics Global Solutions and Macrotech Farmacéutica**

Omics Global Solutions (OGS) was established to launch innovative products based on the "omics" sciences (proteomics, genomics, etc.) to have an impact on the lives of patients, their caregivers, and medical professionals involved with their treatment. Located in Puerto Rico (USA) it has partnered with Macrotech Farmacéutica to serve the population of Latin America.

Macrotech Farmacéutica, established 1995, is a leading health services company and is the exclusive provider of dialysis services, instruments and reagents in the Dominican Republic. The PromarkerD test is branded locally as INNOVATIO ND2.

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

ENDS

#### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Susan Fitzpatrick-Napier [Media Contact]  
Director  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

Paul Hart [Investor Relations]  
Canary Capital  
T: +61 421 051 474  
E: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)